In multicellular organisms, communication between cells involves secretion of proteins that bind to receptors on neighboring cells. While this has been well documented, another mode of intercellular communication has recently become the subject of increasing interest: the release of exosomes. In cancer, tumor exosomes are involved in various aspects of pathogenesis, including proliferation, immunosuppression, and metastasis. Given the ability of exosomes to export unneeded endogenous molecules from cells, these structures hold great potential as anticancer therapeutic agents. They are also being studied as prognostic markers for cancer.

Dating Neurological Injury: A Forensic Guide for Radiologists, Other Expert Medical Witnesses, and Attorneys presents a unique way to approach the dating of neurological injury as imaged by modern computed tomography (CT), magnetic resonance (MR) and ultrasound (US). Chapters are presented in a logical progression beginning with the general appearance of normal brain and progressing to the way abnormalities manifest themselves. The emphasis in these discussions is on the appearance of edema and of hemorrhage, as these two findings are the brain's most common response to injury. This volume presents in a systematic fashion the principles involved in the interpretation of images of the central nervous system specifically in a medical-legal setting where concern exists about the occurrence and timing of an injury. Dating Neurological Injury: A Forensic Guide for Radiologists, Other Expert Medical Witnesses, and Attorneys is a welcome addition to institutional, medical, and legal libraries, and to the personal libraries of malpractice defense and plaintiff lawyers and physicians in the neurosciences (neurosurgery, neurology, neuropathology, and neuroradiology) involved in medical-legal issues.

Given the latest advances in cancer research, which includes basic research and its derived diagnostic, clinical, and therapeutic applications, the book New Trends in Cancer for the 21st Century is written by individuals such as molecular biologists, whose tasks are to decipher, after sequencing the human genome, those new genes and pathways involved in the carcinogenesis process; clinical and molecular pathologists, who apply these discoveries for the molecular diagnosis and characterization of the tumor; and clinical oncologists, who treat patients. Pharmacogenetics introduces new perspectives in the translational fields with the design of drugs against specific targets, which at this moment are in clinical trials phases. Several organizations such as the EORTC (European Organization for Research and Treatment of Cancer) and the OECI (Organization of European Cancer Institutes) and comprehensive cancer centers play a crucial role in focusing cancer research on all these areas.
This book achieves a state of the art in every field of cancer research and discusses the new perspectives that will open the future for cancer treatment (basic research, new technologies, new drugs, therapies...). For this reason, the book is intended for pathologists, clinicians, and biologists, as well as fellows and students of physiology and medicine.

This book provides a comprehensive look at renal cell carcinoma, exploring its biology as well as current and future molecular targets for renal cancer carcinoma.

This entry in the series Pediatric Cancer offers comprehensive information on a variety of cancers, concentrating on brain tumors, the most common solid tumors and the leading cause of cancer-related mortality in children. The contents are organized in seven sections: Neuroblastoma, Medulloblastoma, Leukemia, Lymphoma, Rhabdoid, Sarcoma and Miscellaneous Tumors. Coverage includes pediatric medulloblastoma, and treatments including craniospinal radiation followed by adjuvant chemotherapy. The contributors explain diagnosis and chemotherapy of children with acute lymphoblastic leukemia, and diagnosis of bone marrow involvement in pediatric lymphoma patients. Ewing's sarcoma, a highly malignant connective tissue neoplasm formed by the proliferation of mesenchymal cells, receives extensive coverage, including targeting of molecular pathways and chemotherapy and surgical treatment. The roles of apoptotic genes, MYCN gene, MDM2, and SNP309, P13K inhibitors, alternative splicing and microRNAs, activated leukocyte cell adhesion molecule and inhibition by alu-like RNA in neuroblastoma are discussed in detail. The book explores the molecular genetics, diagnosis, prognosis and therapy of the atypical teratoid/rhabdoid tumor (AT/RT). Among the most common malignant neoplasms in children, AT/RT exhibits similarities with other CNS tumors, which can lead to misclassification, as pointed out in the book. The contributors discuss diagnosis of AT/RT type using imaging technology, and describe new strategies, including intensive multimodal therapy and high dose chemotherapy with autologous stem cell transplantation that have shown improved outcomes. Coverage of therapies includes total resection followed by aggressive chemotherapy and radiation. Discussion includes diagnosis and treatment of other pediatric tumors including adrenocortical tumors, supratentorial primitive neuroectodermal tumors, giant midline tumors, gastrointestinal stromal tumors, ependymomas and intramedullary cavernoma. Pediatric Cancer: Diagnosis, Therapy and Prognosis, Volume 4 includes contributions by ninety-one contributors - oncologists, neurosurgeons, physicians, research scientists and pathologists - representing thirteen countries. The editor, M.A. Hayat, is a Distinguished Professor in the Department of Biological Sciences at Kean University, Union, New Jersey, USA.

Covers all aspects of gastrointestinal and liver malignancies (epidemiology, pathophysiology, screening where appropriate, symptoms and clinical signs, diagnostic studies, staging and classification, treatment, prognosis, follow-up, future perspectives). The text is addressed to those involved in the multidisciplinary approach to the gastrointestinal cancer patient (gastroenterologists, medical oncologists, radiation therapists, surgeons, interventional radiologists, pathologists, nurses, and physicians-in-training). The book provides in-depth information, illustrated by numerous color/black-and-white pictures. Selective reading for a quick reference is made possible by introducing text elements such as summaries, tables, listing and treatment algorithms.

This book will be focused on mitochondria as very promising targets for anti-cancer drugs, yet to be fully exploited. It will contain chapters focused on aspects of basic research as well as on clinical relevance, which will be written by specialists in the field. That the role of mitochondria in human pathologies goes beyond the neoplastic diseases will be documented by a chapter of the role of mitochondria in Friedreich's ataxia.

Prominin-1 or otherwise known as CD133 is a glycoprotein that is present in humans and mice. Since the first description of prominin in 1997, in mouse neuroepithelial cells and in human hematopoietic stem cells as AC133 antigen, this molecule has aroused a large interest especially, as a stem cell marker, that gave rise to an ever growing body of publications and more recently its expression in cancer stem cells. Controversies as to its role as a cancer stem and its detection in different models, as well as its use as a prognostic marker have emerged. Yet, beyond its use as a stem cell and cancer stem cell marker, prominin-1/CD133 displays unique biological features and appears of importance in other processes like for example in retinal biogenesis. Indeed, this five-transmembrane plasma membrane glycoprotein, which marks membrane protrusions is associated with several essential processes like cell polarity, asymmetric cell division and membrane remodeling. We propose to review current knowledge about this intriguing molecule and present pertinent information to determine the biological role of prominins and assess their importance in medicine and cancer research. The primary audience for this book is geared towards scientists and researchers with interest in cancer stem cells, stem cells, cell biology, neurobiology, and regenerative medicine.

The acknowledgment that viruses are potent biological factors in driving many cancers have seen a dramatic upsurge in recent years in large part to the success of the human papilloma virus vaccine against invasive cervical carcinomas and followed by the awarding of the noble prize in medicine in 2008 to Dr. Harald zurHausen who identified the link between papilloma virus and cervical cancers. Over the last few years there have been some volumes addressing different aspects of viruses and cancers and to some extent focusing on the DNA viruses, more specifically the human DNA viruses. This proposed volume will attempt to review and address the major gaps in current knowledge in DNA viruses as well as RNA viruses bringing a historical perspective of where studies began to a more recent molecular approach and vaccine successes in tumor viruses. We will also cover other known oncogenic viruses associated cancers in other mammals in addition to humans.

This book offers comprehensive information on the polymorphisms of genes encoding pattern recognition receptors (PRRs). Following a short description of the general role of PRRs in the immune system, the structure and function of Toll-like and NOD-like receptors are examined in detail. The main focus is on the role of inherited variation in PRRs and their correlation to cancer and cardiovascular diseases. A review of all epidemiological investigations is included, and a concept of genomic risk markers for the prevention of various diseases is also discussed.

There is extremely compelling evidence to suggest that if people are physically active before, during and after cancer treatment, their outcomes are likely to be better. Their risk of recurrence (and death) is lower and their ability to deal with the myriad side effects is improved significantly. Increasingly people with cancer understand this but they are often unsure of what exercise would be best, what is safest, what would be most effective and what to avoid. This book offers very practical, targeted information to enable people to exercise in whatever way they feel ready for. It provides guidance on effective and appropriate exercise for anybody who has received a diagnosis of cancer, including those receiving active treatment and those living with incurable cancer of all types, with the emphasis on the proven benefits of exercise and activity.

This book provides a framework for computational researchers studying the basics of cancer through comparative analyses of omic data. It discusses how key cancer pathways can be analyzed and discovered to derive new insights into the disease and identifies diagnostic and prognostic markers for cancer. Chapters explain the basic cancer biology and how cancer develops, including the many potential survival routes. The examination of gene-expression patterns uncovers commonalities across multiple cancers and specific characteristics of individual cancer types. The authors also treat cancer as an evolving complex system, explore future case studies, and summarize the essential online data sources. Cancer Bioinformatics is designed for practitioners and researchers working in cancer research and bioinformatics. It is also suitable as a secondary textbook for advanced-level students studying computer science, biostatistics or biomedicine.

While it is well established that the worldwide pandemic of overweight and obesity has profound effects on promoting cancer, it is now recognized that an alternative aspect of energy balance, namely physical activity and exercise have significant beneficial effects on all aspects of cancer across the spectrum from prevention through treatment and extending through survivorship. Moreover, salutary effects of physical activity and exercise extend across the age span from youth to old age and occur at all stages of cancer extending into palliative care. While the effect of physical activity and exercise on cancer may be partially mediated through obesity control, it is clear that considerable research is required and is ongoing at both the molecular and clinical levels to better understand the associated mechanisms and to develop optimal exercise strategies. This volume will contain chapters on the effect of exercise on biological pathways in tumor growth, state art exercise strategies and cutting edge research focused on different cancers and patient groups. It will provide an important volume in this series on energy balance and cancer and a basis for ongoing research, experimental approaches and application of evidence based practices to clinical care for patients with cancer. "

This book will be a guide to understanding resistance against targeted therapeutic approaches for cancer using immunotoxins. It contains a detailed review of the history and development of targeted therapy. As well, it includes an in-depth description of the molecular and cellular mechanisms involved in cancer resistance and several novel methods to overcome resistance. Each chapter discusses different aspects of resistance and covers all the factors that may contribute to resistance in cancer cells. Finally, this volume highlights the recent findings and advances associated with tackling cancer resistance.

The book will provide an exhaustive and clear explanation of how Statistics, Mathematics and Informatics have been used in cancer research, and seeks to help cancer researchers in achieving their objectives. To do so, state-of-the-art Biostatistics, Biomathematics and Bioinformatics methods will be described and discussed in detail through illustrative and capital examples taken from cancer research work already published. The book will provide a guide for cancer researchers in using Statistics, Mathematics and Informatics, clarifying the contribution of these logical sciences to the study of cancer, thoroughly explaining their procedures and methods, and providing criteria to their appropriate use.

This volume will describe both growth-inhibitory and mucin-depleting effects of bromelain and N-acetylcysteine, on their own or in combination, in cancer. It will coherently review the pathophysiological aspects of the mucin glycoproteins in malignancies and provide an updated account of the status of bromelain and N-acetylcysteine in cancer therapy. The volume will develop the idea of using these two drugs as a combination formulation for mucin-depleting effects.

This book presents non-linear image enhancement approaches to mammograms as a robust computer-aided analysis solution for the early detection of breast cancer, and provides a compendium of non-linear mammogram enhancement approaches: from the fundamentals to research challenges, practical implementations, validation, and advances in applications. The book includes a comprehensive discussion on breast cancer, mammography, breast anomalies, and computer-aided analysis of mammograms. It also addresses fundamental concepts of mammogram enhancement and associated challenges, and features a detailed review of various state-of-the-art approaches to the enhancement of mammographic images and emerging research gaps. Given its scope, the book offers a valuable asset for radiologists and medical experts (oncologists), as mammogram visualization can enhance the precision of their diagnostic analyses; and for researchers and engineers, as the analysis of non-linear filters is one of the most challenging research domains in image processing.

Management of the Patient at High Risk for Breast Cancer provides a state-of-the art review of patients who are at high risk for breast cancer, how to identify them, the tools available for risk assessment and quantification and indications for genetic counseling and testing. The book summarizes the high risk breast imaging options, including newest techniques and schedules. Pathologic evaluation of high risk lesions are featured as well as the management issues surrounding these lesions. The volume also covers the management of concomitant cancer risk and screening strategies. A concise, yet comprehensive overview of the current status of the topic, Management of the Patient at High Risk for Breast Cancer serves as a useful resource for physicians and researchers dealing with and interested in patients at high risk for breast cancer.

This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy.